– Results confirm IMU-935 as a potent inverse agonist of RORγt with an IC50 of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation – – In addition to its effect on RORγt, IMU-935 is shown to be a DHODH Inhibitor with an IC50 of 240 nM; both mechanisms act synergistically on the reduction of …
Immunic, Inc. to Participate in Investor and Scientific Conferences in June
SAN DIEGO, May 30, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management’s participation in a number of scientific and investor conferences in June: June 3-6: 2nd Conference on Molecular Mechanisms of Inflammation: Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present newly …
Immunic, Inc. to Participate in Upcoming May Conferences
DOWNLOAD PRESENTATION BIOEQUITY EUROPE SAN DIEGO, May 9, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that management will participate in the following conferences in May: May 18-21: Digestive Disease Week® (DDW): Dr. Andreas Muehler, Chief Medical Officer of Immunic, will attend the DDW …
Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer
SAN DIEGO, April 29, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech …
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
– Developing Oral Therapies with Best-in-Class Potential – – Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis – – Proceeds of approximately USD 30 million from concurrent financing to fund clinical development pipeline – – Trading to Commence on The Nasdaq Capital Market under Symbol “IMUX” on April 15, 2019 – SAN …
Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10
LINK TO WEBCAST DOWNLOAD PRESENTATION Planegg-Martinsried, Germany, April 2, 2019 –Immunic AG, a privately held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 4:10 pm ET at the Westin Grand Central Hotel, New York. To view the live webcast, …
Immunic Therapeutics to Participate in Investor and Medical Conferences in March
Download Presentation BioCapital Europe Planegg-Martinsried, Germany, February 28, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced that management will participate in the following conferences in March: March 6-9: 14th Congress of ECCO (European Crohn’s and Colitis Organization) in Copenhagen. Immunic will host Key Opinion Leader meetings on March 7 and 8. Attending from the company …
Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis
Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced enrollment of the first patient in a phase 2 clinical study of IMU-838 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by …
Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11
Link to Webcast Download Presentation Planegg-Martinsried, Germany, February 6, 2019 – Immunic AG (Immunic), a privately-held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019 at 9:45 am ET at the New York Marriott Marquis, in the Chelsea room. To view the live webcast, please follow this …
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
Link to Conference Call Webcast Link to Filed Form S-4 (sec.gov) Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets Lead Program, IMU-838, an Orally Available, Small Molecule Inhibitor of DHODH, Already Advanced into Phase 2 Studies in Ulcerative Colitis Companies to Host Conference Call to Discuss Transaction at …
- Page 1 of 2
- 1
- 2